BioSpace News Archive

Certara, Inc. announced it has acquired Applied BioMath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and de-risk therapeutic research and development.

Fate Therapeutics, Inc. announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 350,000 shares of the Company’s common stock at an exercise price per share of $2.28, which was the closing price per share of the Company’s common stock as reported by NASDAQ on the grant effective date of December 11, 2023.

Merck, known as MSD outside of the United States and Canada, has earned the top spot on Newsweek’s annual list of America’s Most Responsible Companies, ranking No. 1 overall for the first time and establishing itself as an industry leader for the second consecutive year.

Latest Study on “generic pharmaceuticals market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2023-2032”.

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (“MustGrow”) wishes to provide additional information about the collaboration agreement (the “Agreement”) with Bayer AG (“Bayer”) which was announced December 11, 2023.

MCRA, the leading privately held independent medical device, diagnostics, and biologics Clinical Research Organization and advisory firm is pleased to announce the hiring of patient access veteran, Walter Lindstrom, as the new Director of Patient Access Program Operations to its Reimbursement, Healthcare Economics, and Market Access Team.

PharmaDrug Inc. is providing an update from the CEO to elaborate on the reasoning, vision and strategy for the previously announced and executed acquisition of Securedose Synthetics Inc. (“SecureDose”). (See press release dated November 7, 2023).

Value Eyecare Network, a pioneer in innovative eyewear solutions, is thrilled to announce the launch of Neurolux™, a groundbreaking product designed to bring comfort and relief to individuals suffering from migraines, photophobia (light sensitivity), and blepharospasm.

Rapid Medical™, a leading developer of advanced neurovascular devices, announced Japanese approval for its TIGERTRIEVER revascularization device.

Kyverna Therapeutics, Inc. (Kyverna) today announced it received fast track designation by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of myasthenia gravis (MG).